TY  - JOUR
A1  - Bürger, Claudia
A1  - Shirsath, Nitesh
A1  - Lang, Victoria
A1  - Diehl, Sandra
A1  - Kaufmann, Roland
A1  - Weigert, Andreas
A1  - Han, Ying-ying
A1  - Ringel, Christian
A1  - Wolf, Peter
T1  - Blocking mTOR signalling with rapamycin ameliorates imiquimod-induced psoriasis in mice
T2  - Acta dermato-venereologica
N2  - The mTOR (mechanistic target of rapamycin) inhibitor rapamycin has long been known for its immune suppressive properties, but it has shown limited therapeutic success when given systemically to patients with psoriasis. Recent data have shown that the mTOR pathway is hyperactivated in lesional psoriatic skin, which probably contributes to the disease by interfering with maturation of keratinocytes. This study investigated the effect of topical rapamycin treatment in an imiquimod-induced psoriatic mouse model. The disease was less severe if the mice had received rapamycin treatment. Immunohistological analysis revealed that rapamycin not only prevented the activation of mTOR signalling (P-mTOR and P-S6 levels), but almost normalized the expression of epidermal differentiation markers. In addition, the influx of innate immune cells into the draining lymph nodes was partially reduced by rapamycin treatment. These data emphasize the role of mTOR signalling in the pathogenesis of psoriasis, and support the investigation of topical mTOR inhibition as a novel anti-psoriatic strategy.
KW  - psoriasis
KW  - imiquimod
KW  - rapamycin
KW  - mTORC
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45069
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-450697
SN  - 1651-2057
SN  - 0001-5555
N1  - This is an open access article under the CC BY-NC license
VL  - 97
IS  - 9
SP  - 1087
EP  - 1094
PB  - Acta Dermato-Venereologica
CY  - Uppsala
ER  -